Abstract
Background: Esophageal carcinoma is one of the common malignant tumors in digestive tract. BECLIN-1 is a key gene that regulates autophagy, and its abnormal expression may be related with many human tumors. However, the mechanism of BECLIN-1 in esophageal carcinoma remains unknown.
Objective: In this study, we explored the effect of BECLIN-1 overexpression on tumor growth in mice with esophageal carcinoma and its mechanism.
Methods: Recombined lentiviral vector containing BECLIN-1 was used to transfect human esophageal carcinoma Eca109 cells and establish stable cell line. qRT-PCR was used to detect BECLIN-1 mRNA level in the transfected Eca109 cells, CCK-8 assay was used to detect cell proliferation. Beclin-1, P62 and LC3-II protein expression levels in Eca109 cells were detected using Western blot analysis. Subcutaneous xenograft nude mice model of human esophageal carcinoma was established, and the tumor growths in Beclin-1 group, control group and empty vector group were monitored. Beclin-1 protein expression in vivo was detected by immunohistochemistry.
Results: Beclin-1 mRNA and protein were overexpressed in Eca109 cells. Compared with empty vector group, the growth rate of cells transfected with BECLIN-1 decreased significantly. Compared with the control group and empty vector group, the expression level of P62 protein in beclin-1 group was significantly decreased, while the expression level of LC3-II protein was significantly increased. The tumor growth rate in nude mice of Beclin-1 group was significantly lower than that of the control group and empty vector group, and Beclin-1 protein was mainly expressed in Beclin-1 group in vivo.
Conclusion: BECLIN-1 can induce autophagy in esophageal carcinoma Eca109 cells, and it can significantly inhibit the growth of esophageal carcinoma.
Keywords: Autophagy, Beclin-1, esophageal carcinoma, lentiviral vector, proliferation, tumor growth.
[http://dx.doi.org/10.3390/ijerph14020155] [PMID: 28178195]
[http://dx.doi.org/10.21873/anticanres.12852] [PMID: 30194177]
[http://dx.doi.org/10.1590/0102-6720201600030003] [PMID: 27759773]
[http://dx.doi.org/10.1080/10717544.2016.1225854] [PMID: 28155336]
[http://dx.doi.org/10.3892/mmr.2017.6145] [PMID: 28138712]
[http://dx.doi.org/10.1186/s12876-017-0590-0] [PMID: 28212604]
[http://dx.doi.org/10.4161/auto.1.2.1738] [PMID: 16874022]
[http://dx.doi.org/10.1007/s00018-004-4012-4] [PMID: 15197469]
[http://dx.doi.org/10.1080/15548627.2018.1489170] [PMID: 29969942]
[http://dx.doi.org/10.1007/s11596-013-1203-y] [PMID: 24337840]
[http://dx.doi.org/10.18632/oncotarget.10779] [PMID: 27462775]
[http://dx.doi.org/10.3727/096504016X14719078133285] [PMID: 28081732]
[http://dx.doi.org/10.15252/embj.201490784] [PMID: 25712477]
[http://dx.doi.org/10.1016/j.ab.2017.05.003] [PMID: 28477964]
[http://dx.doi.org/10.1016/j.yexcr.2017.12.027] [PMID: 29289595]
[http://dx.doi.org/10.1016/j.ygyno.2018.04.557] [PMID: 29699801]
[PMID: 26722036]
[http://dx.doi.org/10.1016/j.coph.2018.04.003] [PMID: 29677645]
[http://dx.doi.org/10.2174/1574892811666160822161157] [PMID: 27549139]
[http://dx.doi.org/10.2174/1574892814666181231142136] [PMID: 30599110]
[http://dx.doi.org/10.3748/wjg.v23.i3.540] [PMID: 28210091]
[http://dx.doi.org/10.3748/wjg.v23.i3.478] [PMID: 28210084]
[http://dx.doi.org/10.1097/SLA.0000000000001692] [PMID: 28169928]
[http://dx.doi.org/10.1111/nyas.13190] [PMID: 27526024]
[http://dx.doi.org/10.3892/or.2016.4753] [PMID: 27109915]
[http://dx.doi.org/10.1111/j.1365-2184.2012.00845.x] [PMID: 23030059]
[http://dx.doi.org/10.1016/j.prp.2013.06.006] [PMID: 23880165]
[http://dx.doi.org/10.1152/ajpgi.00340.2011] [PMID: 22301112]
[http://dx.doi.org/10.3892/ol.2016.5367] [PMID: 28105213]
[http://dx.doi.org/10.18632/oncotarget.14566] [PMID: 28088783]